Table 3

Risk of major adverse liver outcomes according to intention-to-treat and per-protocol analyses

No of events, GLP1 agonist initiatorsNo of events, non-initiatorsAbsolute risk (%), GLP1 agonist initiators
(95% CI)
Absolute risk (%), non-initiators
(95% CI)
Risk difference (%) (95% CI)Risk ratio (95% CI)
Intention to treat
2 years164362.3 (1.0 to 3.6)3.2 (2.9 to 3.5)−0.9 (−2.2 to 4.3)0.72 (0.31 to 1.13)
4 years317566.6 (3.4 to 9.9)6.4 (6.0 to 6.9)0.2 (−3.1 to 3.5)1.03 (0.52 to 1.54)
6 years369338.0 (4.5 to 11.6)9.1 (8.4 to 9.7)−1.0 (−4.6 to 2.5)0.89 (0.50 to 1.27)
8 years41103611.6 (7.0 to 16.3)11.8 (10.9 to 12.8)−0.2 (−4.8 to 4.4)0.98 (0.59 to 1.38)
10 years42107913.3 (7.4 to 19.2)14.6 (13.1 to 16.1)−1.3 (−7.2 to 4.6)0.91 (0.50 to 1.32)
Per protocol
2 years134362.6 (0.9 to 4.3)3.2 (2.9 to 3.5)−0.6 (−2.4 to 1.1)0.80 (0.26 to 1.34)
4 years197564.5 (2.1 to 7.0)6.3 (5.9 to 6.9)−1.9 (−4.3 to 0.6)0.71 (0.32 to 1.10)
6 years219335.4 (2.7 to 8.1)9.0 (8.4 to 9.7)−3.6 (−6.4 to 0.8)0.60 (0.29 to 0.90)
8 years2210367.2 (2.5 to 11.9)11.7 (10.8 to 12.7)−4.6 (−9.3 to 0.1)0.61 (0.21 to 1.01)
10 years2210797.4 (2.1 to12.6)14.4 (12.9 to 15.9)−7.1 (−12.5 to 1.6)0.51 (0.14 to 0.88)
  • .GLP1, glucagon-like peptide-1 receptor.